Stock of the Day
September 13, 2024
AnaptysBio (ANAB)
$21.84
+$0.70 (+3.3%)
Market Cap:
$641.51M
About AnaptysBio
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
← Previous Stock of the Day
Next Stock of the Day →
Recent News
HC Wainwright & Co. Upgrades AnaptysBio (ANAB)
(msn.com)
Anaptys gains after updated data from mid-stage trial for arthritis therapy
(msn.com)
J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent
(msn.com)
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
(benzinga.com)
AnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA Trial
(insidermonkey.com)
AnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment Rosnilimab
(marketwatch.com)
Stocks Generating Improved Relative Strength: AnaptysBio
(msn.com)
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
(globenewswire.com)
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
(benzinga.com)